First in-human evaluation of [1- 13 C]pyruvate in D 2 O for hyperpolarized MRI of the brain: A safety and feasibility study.

Autor: Deh K; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Zhang G; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Park AH; Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center, New York, New York, USA., Cunningham CH; Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Bragagnolo ND; Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada., Lyashchenko S; Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center, New York, New York, USA., Ahmmed S; Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center, New York, New York, USA., Leftin A; General Electric Healthcare, New York, New York, USA., Coffee E; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Hricak H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Miloushev V; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Mayerhoefer M; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Keshari KR; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jazyk: angličtina
Zdroj: Magnetic resonance in medicine [Magn Reson Med] 2024 Jun; Vol. 91 (6), pp. 2559-2567. Date of Electronic Publication: 2024 Jan 11.
DOI: 10.1002/mrm.30002
Abstrakt: Purpose: To investigate the safety and value of hyperpolarized (HP) MRI of [1- 13 C]pyruvate in healthy volunteers using deuterium oxide (D 2 O) as a solvent.
Methods: Healthy volunteers (n = 5), were injected with HP [1- 13 C]pyruvate dissolved in D 2 O and imaged with a metabolite-specific 3D dual-echo dynamic EPI sequence at 3T at one site (Site 1). Volunteers were monitored following the procedure to assess safety. Image characteristics, including SNR, were compared to data acquired in a separate cohort using water as a solvent (n = 5) at another site (Site 2). The apparent spin-lattice relaxation time (T 1 ) of [1- 13 C]pyruvate was determined both in vitro and in vivo from a mono-exponential fit to the image intensity at each time point of our dynamic data.
Results: All volunteers completed the study safely and reported no adverse effects. The use of D 2 O increased the T 1 of [1- 13 C]pyruvate from 66.5 ± 1.6 s to 92.1 ± 5.1 s in vitro, which resulted in an increase in signal by a factor of 1.46 ± 0.03 at the time of injection (90 s after dissolution). The use of D 2 O also increased the apparent relaxation time of [1- 13 C]pyruvate by a factor of 1.4 ± 0.2 in vivo. After adjusting for inter-site SNR differences, the use of D 2 O was shown to increase image SNR by a factor of 2.6 ± 0.2 in humans.
Conclusions: HP [1- 13 C]pyruvate in D 2 O is safe for human imaging and provides an increase in T 1 and SNR that may improve image quality.
(© 2024 International Society for Magnetic Resonance in Medicine.)
Databáze: MEDLINE
Externí odkaz: